Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 533,000 shares, anincreaseof330.5% from the June 30th total of 123,800 shares. Approximately18.0% of the shares of the stock are short sold. Based on an average trading volume of 824,700 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 824,700 shares, the days-to-cover ratio is presently 0.6 days. Approximately18.0% of the shares of the stock are short sold.
Hedge Funds Weigh In On Clearmind Medicine
A hedge fund recently raised its stake in Clearmind Medicine stock. Citadel Advisors LLC grew its holdings in Clearmind Medicine Inc. (NASDAQ:CMND – Free Report) by 115.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,158 shares of the company’s stock after purchasing an additional 20,429 shares during the quarter. Citadel Advisors LLC owned about 0.89% of Clearmind Medicine worth $53,000 as of its most recent SEC filing. 96.05% of the stock is owned by hedge funds and other institutional investors.
Clearmind Medicine Price Performance
Shares of NASDAQ:CMND opened at $0.98 on Tuesday. Clearmind Medicine has a 1 year low of $0.80 and a 1 year high of $2.18. The firm has a market capitalization of $4.18 million, a PE ratio of -0.89 and a beta of 0.95. The business’s 50 day moving average price is $0.96 and its 200-day moving average price is $1.08.
Clearmind Medicine Company Profile
Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
Featured Articles
- Five stocks we like better than Clearmind Medicine
- How Technical Indicators Can Help You Find Oversold Stocks
- Analysts Make a Quantum Bet on D-Wave’s Cryogenic Packaging
- Do ETFs Pay Dividends? What You Need to Know
- Traders Turn Bullish on Housing Stocks Again—3 Leading the Way
- What Are Growth Stocks and Investing in Them
- Onsemi’s August Pullback Is a Signal to Buy for Tech Investors
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.